New Perspectives for the Administration of Cannabis for Medical Use: From Traditional to Advanced Formulations. What Next?

Dear Colleagues,

Before it became illegal in most parts of the world in the previous century, cannabis was widely used in medicine. In recent years, following the legalization of cannabinoids for medical use in various countries, there has been an exponential increase in its use and a growing interest in this field. Therefore, scientific research on medical cannabis has rapidly advanced, and the ever-increasing number of experimental studies suggests that phytocannabinoids could be useful for various pathological conditions.

The phytocomplex of cannabis plants is composed of over 500 different constituents, of which about a hundred belong to the class of cannabinoids, where minimal differences in their structure can induce very different effects. The molecules of greatest interest for their pharmacological activity are THC and CBD, but recent studies have also focused on the effects of other molecules, such as cannabigerols, cannabichromenes, and also terpenes.

This Special Issue of Pharmaceutics focuses on articles and reviews relating to extractive or advanced formulations based on cannabis for medical use, currently under study for therapeutic purposes. Studies relating to the development of galenic formulations will also be considered.

We look forward to receiving your contributions.

Dr. Paola Brusa
Dr. Francesca Baratta
Prof. Dr. Fabio Firenzuoli
Dr. Valentina Maggini
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.